CA3172535A1 - Cyclophilin inhibitors and uses thereof - Google Patents

Cyclophilin inhibitors and uses thereof Download PDF

Info

Publication number
CA3172535A1
CA3172535A1 CA3172535A CA3172535A CA3172535A1 CA 3172535 A1 CA3172535 A1 CA 3172535A1 CA 3172535 A CA3172535 A CA 3172535A CA 3172535 A CA3172535 A CA 3172535A CA 3172535 A1 CA3172535 A1 CA 3172535A1
Authority
CA
Canada
Prior art keywords
compound
organ
alkyl
formula
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3172535A
Other languages
English (en)
French (fr)
Inventor
Ching-Pong Mak
Hans Fliri
Fashu MA
Michael Peel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farsight Medical Technology Shanghai Co Ltd
Original Assignee
Farsight Medical Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farsight Medical Technology Shanghai Co Ltd filed Critical Farsight Medical Technology Shanghai Co Ltd
Publication of CA3172535A1 publication Critical patent/CA3172535A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Analytical Chemistry (AREA)
CA3172535A 2020-03-26 2021-03-25 Cyclophilin inhibitors and uses thereof Pending CA3172535A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/081295 2020-03-26
CN2020081295 2020-03-26
CN2021078391 2021-03-01
CNPCT/CN2021/078391 2021-03-01
PCT/CN2021/083013 WO2021190601A1 (en) 2020-03-26 2021-03-25 Cyclophilin inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CA3172535A1 true CA3172535A1 (en) 2021-09-30

Family

ID=77891510

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3172535A Pending CA3172535A1 (en) 2020-03-26 2021-03-25 Cyclophilin inhibitors and uses thereof
CA3172601A Pending CA3172601A1 (en) 2020-03-26 2021-03-25 Preparation of cyclosporin derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3172601A Pending CA3172601A1 (en) 2020-03-26 2021-03-25 Preparation of cyclosporin derivatives

Country Status (13)

Country Link
US (3) US12673976B2 (cg-RX-API-DMAC10.html)
EP (2) EP4126905B1 (cg-RX-API-DMAC10.html)
JP (2) JP7761578B2 (cg-RX-API-DMAC10.html)
KR (2) KR20220158760A (cg-RX-API-DMAC10.html)
CN (2) CN115335389A (cg-RX-API-DMAC10.html)
AU (1) AU2021240762A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018929A2 (cg-RX-API-DMAC10.html)
CA (2) CA3172535A1 (cg-RX-API-DMAC10.html)
ES (1) ES3074820T3 (cg-RX-API-DMAC10.html)
IL (1) IL296586B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022011697A (cg-RX-API-DMAC10.html)
TW (1) TWI917366B (cg-RX-API-DMAC10.html)
WO (2) WO2021190601A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途
CN116870135A (zh) 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
GB202207348D0 (en) * 2022-05-19 2022-07-06 Cypralis Ltd Macrocyclic compounds and uses thereof
TW202438040A (zh) * 2023-03-03 2024-10-01 大陸商睿諾醫療科技(上海)有限公司 劑誘導的肝臟病症或疾病的治療和預防
WO2024245384A1 (en) * 2023-06-02 2024-12-05 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof
WO2026119135A1 (en) * 2024-12-03 2026-06-11 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
DE69832984T2 (de) * 1997-10-08 2006-09-21 Isotechnika, Inc., Edmonton DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
ATE254630T1 (de) 1998-06-12 2003-12-15 Chem Ag C Cyclosporine
US6809077B2 (en) 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
DK1436322T3 (da) 2001-10-19 2008-11-03 Isotechnika Inc Blandinger af cyclosporinanaloger og deres anvendelse som immunmodulerende midler
CA2518265A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
JP2007532507A (ja) * 2004-04-08 2007-11-15 ノバルティス アクチエンゲゼルシャフト 脳虚血ならびに脳および脊髄傷害の処置のためのサイクロスポリンの使用
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
CN101068829B (zh) * 2004-10-01 2012-05-30 西尼克斯公司 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
CA2652662C (en) * 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
WO2008143996A1 (en) * 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
MX2011001152A (es) 2008-07-30 2011-06-09 Isotechnika Pharma Inc Moleculas de analogo de ciclosporina no-inmunesupresoras.
RU2492181C2 (ru) 2009-01-30 2013-09-10 Энанта Фармасьютикалс, Инк. Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
CA2785978A1 (en) * 2009-12-30 2011-07-07 Scynexis, Inc. Cyclosporine analogues
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
DE102011111991A1 (de) 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
GB201217560D0 (en) 2012-10-02 2012-11-14 Mitopharm Ltd Novel cyclic depsipeptide compounds and their uses
US20140213508A1 (en) 2012-10-19 2014-07-31 Scynexis, Inc. Antiviral macrocycles
GB201222455D0 (en) 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
CN108025039B (zh) 2015-06-30 2022-07-29 西普拉里斯有限公司 新颖的大环化合物
CN106902347A (zh) * 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 亲环孢素抑制剂的用途
CN106902346A (zh) 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 药物组合物及其制药用途
AU2017267560B2 (en) * 2016-05-17 2022-03-24 S&T Global Inc. Novel cyclosporin derivatives and uses thereof
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
WO2020037530A1 (en) 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
CN111449050A (zh) 2019-01-20 2020-07-28 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途
CN116870135A (zh) 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries

Also Published As

Publication number Publication date
US20240352074A1 (en) 2024-10-24
AU2021240762A1 (en) 2022-10-06
EP4126905C0 (en) 2026-05-13
TW202144379A (zh) 2021-12-01
KR20220158760A (ko) 2022-12-01
MX2022011697A (es) 2022-10-07
KR20220158761A (ko) 2022-12-01
CA3172601A1 (en) 2021-09-30
IL296586B1 (en) 2026-04-01
EP4126904A1 (en) 2023-02-08
US20230174583A1 (en) 2023-06-08
ES3074820T3 (es) 2026-07-23
US12522634B2 (en) 2026-01-13
CN115298199A (zh) 2022-11-04
JP7761578B2 (ja) 2025-10-28
EP4126905B1 (en) 2026-05-13
US12673976B2 (en) 2026-07-07
TWI917366B (zh) 2026-03-11
EP4126905A1 (en) 2023-02-08
WO2021190604A1 (en) 2021-09-30
US20230110497A1 (en) 2023-04-13
JP2023518776A (ja) 2023-05-08
EP4126905A4 (en) 2024-05-29
IL296586A (en) 2022-11-01
IL296586B2 (en) 2026-08-01
JP2023518777A (ja) 2023-05-08
WO2021190601A1 (en) 2021-09-30
EP4126904A4 (en) 2024-05-29
JP7776435B2 (ja) 2025-11-26
BR112022018929A2 (pt) 2022-12-06
CN115335389A (zh) 2022-11-11
US12060440B2 (en) 2024-08-13

Similar Documents

Publication Publication Date Title
US12522634B2 (en) Cyclophilin inhibitors and uses thereof
US20040138147A1 (en) Compounds and methods for treating transplant rejection
AU2021244763A1 (en) Cyclophilin inhibitors and uses thereof
EP3655012B1 (en) Cyclosporin analogues and uses thereof
JP6453441B2 (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ2a阻害剤
JP6661533B2 (ja) ミトコンドリアを標的とするジカルボニル捕捉化合物
US20080051428A1 (en) Pyrroloquinoline quinone drugs and methods of use thereof
JP2007535525A (ja) β−カルボリン誘導体を含有する医薬組成物および癌を処置するためのそれらの使用
CN116077631A (zh) 涉及粘液素的疾病治疗
AU2020346898B2 (en) Phospholipid ether conjugates as cancer-targeting drug vehicles
JP2009535410A (ja) ピロロキノリンキノンおよびその使用
AU2017265037B2 (en) Compounds for the treatment of ischemia-reperfusion-related diseases
EA051978B1 (ru) Ингибиторы циклофилина и их применение
KR20050039700A (ko) 이식거부 치료용 화합물 및 치료 방법
HK40027251A (en) Cyclosporin analogues and uses thereof
HK40027251B (en) Cyclosporin analogues and uses thereof
Rodríguez et al. on Nephrotoxicity
KR20170110520A (ko) mTOR 억제제 및 N-아세틸시스테인을 포함하는 간섬유화 억제용 조성물

Legal Events

Date Code Title Description
P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250310

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250311

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250317

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250317

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250331

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250331

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250331

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250514

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260316

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260316